Shenzhen Kaifa Technology
920029
Shanghai Yongli Belting
300230
Guomai Culture & Media
301052
4
WuHan Hvsen Biotechnology
300871
5
CHANGFU CO.,LTD
871396
US Stock MarketDetailed Quotes
TARS Tarsus Pharmaceuticals
- 51.740
- +1.090+2.15%
Close Mar 28 16:00 ET
- 51.740
- 0.0000.00%
Post 20:01 ET
2.13BMarket Cap-16.85P/E (TTM)
52.300High49.555Low499.10KVolume50.580Open50.650Pre Close25.66MTurnover1.56%Turnover RatioLossP/E (Static)41.19MShares57.28052wk High9.49P/B1.66BFloat Cap20.08252wk Low--Dividend TTM32.01MShs Float63.690Historical High--Div YieldTTM5.42%Amplitude10.800Historical Low51.407Avg Price1Lot Size
Tarsus Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 948.62%182.95M | 407.86%66.41M | 2,471.78%48.12M | 40.81M | 1,004.56%27.61M | -32.42%17.45M | 30.76%13.08M | 1.87M | 0 | 363.82%2.5M |
| Operating revenue | 948.62%182.95M | 407.86%66.41M | 2,471.78%48.12M | --40.81M | 1,004.56%27.61M | -32.42%17.45M | 30.76%13.08M | --1.87M | --0 | 363.82%2.5M |
| Cost of revenue | 705.15%12.83M | 305.10%4.93M | 759.95%3.24M | 3M | 1.65M | 66.81%1.59M | 204.00%1.22M | 377K | 0 | 0 |
| Gross profit | 973.09%170.13M | 418.40%61.48M | 2,903.75%44.88M | 37.81M | 938.40%25.96M | -36.23%15.85M | 23.54%11.86M | 1.49M | 0 | 394.07%2.5M |
| Operating expense | 82.81%290.7M | 52.55%85.9M | 65.07%70.04M | 116.66%71.11M | 131.84%63.64M | 81.58%159.01M | 128.34%56.31M | 85.23%42.43M | 64.28%32.82M | 37.07%27.45M |
| Selling and administrative expenses | 118.32%237.31M | 60.52%69.03M | 90.97%57.91M | 189.97%58.79M | 241.67%51.58M | 141.83%108.7M | 193.89%43.01M | 152.83%30.32M | 95.40%20.28M | 89.98%15.1M |
| Research and development costs | 6.11%53.39M | 26.82%16.87M | 0.19%12.13M | -1.81%12.32M | -2.35%12.07M | 18.04%50.31M | 32.68%13.31M | 10.93%12.11M | 30.65%12.55M | 2.28%12.36M |
| Operating profit | 15.78%-120.57M | 45.06%-24.42M | 38.53%-25.16M | -1.47%-33.3M | -51.03%-37.68M | -128.28%-143.16M | -195.13%-44.45M | -78.71%-40.94M | -528.27%-32.82M | -27.82%-24.95M |
| Net non-operating interest income expense | 2.49%7.17M | -32.88%1.34M | -15.49%1.68M | 43.23%2.02M | 32.63%2.13M | 437.77%6.99M | 38.61%1.99M | 363.08%1.98M | 671.26%1.41M | 609.18%1.61M |
| Non-operating interest income | 45.25%15.01M | 22.46%3.65M | 45.07%4.12M | 85.53%4.13M | 35.94%3.12M | 195.43%10.34M | 40.01%2.98M | 167.67%2.84M | 649.49%2.23M | --2.29M |
| Non-operating interest expense | 130.91%7.45M | 126.93%2.17M | 180.73%2.32M | 155.15%2.01M | 44.89%949K | 56.25%3.23M | 44.71%958K | 40.55%825K | 44.67%787K | 107.28%655K |
| Total other finance cost | 232.23%402K | 345.16%138K | 290.91%129K | 260.71%101K | 17.24%34K | -10.37%121K | 3.33%31K | -28.26%33K | --28K | --29K |
| Other net income (expense) | -884.67%-2.15M | -104.83%-27K | 134.36%67K | -14,250.00%-2.01M | -138.16%-181K | 140.12%274K | 1,970.37%559K | -413.16%-195K | 94.85%-14K | 81.00%-76K |
| Gain on sale of security | -310.64%-792K | --0 | ---- | -118.18%-6K | -858.54%-786K | 148.89%376K | 642.86%572K | -374.19%-147K | 108.73%33K | 81.24%-82K |
| Special income (charges) | ---1.94M | --0 | --0 | ---1.94M | ---- | --0 | --0 | --0 | --0 | ---- |
| -Less:Other special charges | --1.94M | --0 | ---- | --1.94M | ---- | ---- | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | 674.51%586K | -107.69%-27K | 239.58%67K | -25.53%-59K | 9,983.33%605K | -218.60%-102K | 74.00%-13K | -585.71%-48K | -144.34%-47K | -83.78%6K |
| Income before tax | 14.97%-115.55M | 44.84%-23.11M | 40.18%-23.42M | -5.94%-33.29M | -52.57%-35.73M | -118.85%-135.89M | -208.13%-41.9M | -73.87%-39.15M | -447.17%-31.42M | -15.72%-23.42M |
| Income tax | 0 | 0 | ||||||||
| Net income | 14.97%-115.55M | 44.84%-23.11M | 40.18%-23.42M | -5.94%-33.29M | -52.57%-35.73M | -118.86%-135.89M | -208.13%-41.9M | -73.91%-39.15M | -447.17%-31.42M | -15.72%-23.42M |
| Net income continuous Operations | 14.97%-115.55M | 44.84%-23.11M | 40.18%-23.42M | -5.94%-33.29M | -52.57%-35.73M | -118.86%-135.89M | -208.13%-41.9M | -73.91%-39.15M | -447.17%-31.42M | -15.72%-23.42M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 14.97%-115.55M | 44.84%-23.11M | 40.18%-23.42M | -5.94%-33.29M | -52.57%-35.73M | -118.86%-135.89M | -208.13%-41.9M | -73.91%-39.15M | -447.17%-31.42M | -15.72%-23.42M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 14.97%-115.55M | 44.84%-23.11M | 40.18%-23.42M | -5.94%-33.29M | -52.57%-35.73M | -118.86%-135.89M | -208.13%-41.9M | -73.91%-39.15M | -447.17%-31.42M | -15.72%-23.42M |
| Basic earnings per share | 33.55%-3.07 | 54.20%-0.6 | 52.34%-0.61 | 24.79%-0.88 | -14.77%-1.01 | -83.33%-4.62 | -167.35%-1.31 | -52.38%-1.28 | -387.50%-1.17 | 10.20%-0.88 |
| Diluted earnings per share | 33.55%-3.07 | 54.20%-0.6 | 52.34%-0.61 | 24.79%-0.88 | -14.77%-1.01 | -83.33%-4.62 | -167.35%-1.31 | -51.61%-1.28 | -387.50%-1.17 | 10.20%-0.88 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call